BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, March 5, 2026
Home » Topics » Regulatory

Regulatory
Regulatory RSS Feed RSS

Regulatory actions for Aug. 24, 2023

Aug. 24, 2023
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Paragonix.
Read More
EU flags at European Commission building

The EC releases update on MDR-IVDR applications and certification

Aug. 24, 2023
By Bernard Banga
The European Commission’s (EC’s) Directorate-General for Health and Food Safety recently published a survey of notified bodies. This was conducted between April and May 2023, eliciting responses from all 39 notified bodies designated under the Medical Devices Regulation (MDR) and 10 Notified bodies designated under the In Vitro Diagnostic Regulation (IVDR).
Read More
Imeka white matter tracking

FDA clearance, reimbursement codes greet Imeka’s white matter tracking tool

Aug. 24, 2023
By David Godkin
Imeka Solutions Inc. has received U.S. FDA 510(k) clearance for the Advanced Neuro Diagnostic Imaging system designed to provide neurologists and radiologists with vital reference information on cerebral white matter for better management of brain diseases such as Alzheimer’s. This comes on the heels of two new CPT 3 codes for quantitative brain MRI assessment which Imeka expects its clients will begin taking advantage of by January 2024.
Read More
Medtronic - Symplicty Spyral HTN

Divergent trial results tank Medtronic’s Symplicity Spyral at FDA advisory

Aug. 24, 2023
By Mark McCarty
Dublin-based Medtronic plc. has invested considerable resources into its renal denervation program, but the company has not completed its regulatory journey for the U.S. market just yet. Medtronic failed to persuade an FDA advisory committee of the virtues of its Symplicity Spyral device due to inconsistent results from the two major studies presented at the hearing but vowed to keep working on the application despite the sustained headwinds.
Read More

Regulatory actions for Aug. 23, 2023

Aug. 23, 2023
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Akava, Amgen, Fulcrum, Geron, Janssen, Nascent, Pfizer, Vigeneron, Vincerx.
Read More

Regulatory actions for Aug. 23, 2023

Aug. 23, 2023
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Fresenius, Geneseeq, Pixcell, Sparrow Bioacoustics, Telesair.
Read More

US FTC taps Covington’s Liu for director of Bureau of Competition

Aug. 23, 2023
By Mark McCarty
The U.S. Federal Trade Commission has picked Henry Liu of the law firm of Covington & Burling to run the agency’s Bureau of Competition, a seat that was vacated earlier this year when Holly Vedova retired.
Read More
Levita Magnetics’ MARS system

FDA gives Levita a lift to MARS with surgery system clearance

Aug. 23, 2023
By Annette Boyle
Levita Magnetics International Corp. received uplifting news this week as the U.S. FDA cleared its magnetic-Assisted Robotic Surgery (MARS) minimally invasive surgical platform. MARS builds on the company’s first product, the Levita magnetic surgical system, by providing greater control of surgical instruments to surgeons. The platform is cleared for use in bariatric, colorectal, gallbladder and prostate surgeries.
Read More
Recor Medicaal Paradise renal denervation catheter

Recor snares supportive vote from FDA advisory panel for Paradise renal denervation device

Aug. 23, 2023
By Mark McCarty
The age of renal denervation as a treatment for hypertension may have finally arrived in the U.S. with the affirmative U.S. FDA advisory vote for the Paradise system for renal denervation by Recor Medical Inc., of Palo Alto, Calif. The 12-member advisory committee vote unanimously that the data suggested the ultrasound-based device was safe and voted 8-3 in support of the Paradise’s efficacy, an outcome that the agency may find difficult to refute, given the large public health impact of hypertension in the U.S.
Read More
Illustration demonstrating muscle contraction in amyotrophic lateral sclerosis.
Neurology/Psychiatric

Akava announces IND clearance for AKV-9 to enter clinic for ALS

Aug. 23, 2023
Akava Therapeutics Inc. has announced FDA clearance of its IND application for AKV-9 (formerly NU-9) for the treatment of amyotrophic lateral sclerosis (ALS). The company is planning a first-in-human phase I study in healthy subjects.
Read More
Previous 1 2 … 326 327 328 329 330 331 332 333 334 … 1346 1347 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for March 4, 2026.
  • Brain and virus with chromosome

    CROI 2026: Neurodegeneration, the challenge of aging with HIV

    BioWorld
    Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...
  • Depression concept with human, broken brain and heavy rain

    CROI 2026 highlights depression and cognitive vulnerability in HIV

    BioWorld
    The effects of aging pose an additional challenge for people with HIV due to the neurological and psychological consequences that persist despite antiretroviral...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for March 3, 2026
  • Concept art for headache

    Slate Medicines launches with focus on headache disorders

    BioWorld Science
    Slate Medicines Inc. has launched with $130 million in series A financing and a focus on advancing next-generation therapeutics for migraine and other headache...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing